Covid-19 vaccine set to be one of Pfizer’s best sellers
Bloomberg (29 July 2021) reported that the pharmaceutical manufacturer Pfizer is expecting its Covid-19 vaccine to bring in revenue of $33.5-bn in 2021, which could make it one of the best-selling medicines on record. The drugmaker previously projected vaccine sales of $26-bn for the year. The upward revision is a sign that demand for the shots, which Pfizer sells with German partner BioNTech, is surging as countries battle outbreaks fuelled by the Delta virus variant. If Pfizer meets its sales projections the vaccine would climb into the highest rank of blockbuster medicines, outpacing bellwethers such as AbbVie’s Humira immunosuppressive therapy and Merck cancer fighter Keytruda.
Earlier this month, Pfizer said it would approach US regulators for authorisation of a third booster dose of its vaccine, based on early data showing that it can sharply increase immune protection against the coronavirus. Pfizer also aims to create a new formulation of the vaccine tailored to combat the Delta variant.